ImmunityBio, Inc.

NASDAQ:IBRX

Biotechnology

Healthcare
$6.70 +2.58%

+$0.18 today

Market cap
$7.13B
Beta
0.10
P/E (TTM)
-8.6
EPS (TTM)
-$0.83
52W Low $1.95High $12.43

Volume 15.77M

Average 16.40M

IBRX Weighted Avg Shares

Average number of basic shares outstanding during the period, used to calculate basic EPS.

ImmunityBio, Inc.NASDAQ: IBRX

Weighted Avg Shares · Q3 FY2026 · quarter ended Sep 2026

Weighted avg shares grows, but more slowly than its trailing trend

Q3 FY2026 weighted avg shares of 1.06B shares rose 12.0% year over year, behind the +20.6% change in trailing-twelve-month weighted avg shares. Sequentially, it rose 1.0% from the prior quarter. Over 3 fiscal years it compounded at +32.0% a year.

Context

  • Weighted avg shares increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from +12.0% toward the trailing-twelve-month pace of +20.6%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterSep 2026
1.06B+1.0% QoQ
Last fiscal yearDec 2025
919.86M+31.9% YoY
LTMSep 2026
1.03B+20.6% YoY
Weighted Avg Shares past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+12.0%——
1 year+31.9%——
3-year CAGR+32.0%——
5-year CAGR——
10-year CAGR——

Weighted Avg Shares history

Shares · from the income statement

Latest · FY2025
919.86M USD
Year-over-year change
+31.9%
4-year CAGR
+24.0%

Weighted Avg Shares vs competitors

How IBRX compares with its peers on the latest reported figures

  • IBRX's LTM Sep 2026 weighted avg shares of 1.03B shares is the highest of the 11 companies compared; the peer median is 163.43M shares.
  • Its year-over-year change of +20.6% is the 3rd highest of 11, against a peer median of +3.0%.
  • Over three fiscal years its annual growth of +32.0% compares with a peer median of +10.3%.
IBRX Competitors Peer median
Weighted Avg Shares for IBRX and competitors
Company Period LTM YoY 3-year CAGR
IBRXImmunityBio, Inc.LTM Sep 20261.03B +20.6%+32.0%
IOVAIovance Biotherapeutics, Inc.LTM Sep 2026432.9M +30.6%+30.9%
MRNAModerna, Inc.LTM Sep 2026396M +2.3%-0.4%
BNTXBioNTech SELTM Jun 2026247.64M +3.0%-0.2%
ALLOAllogene Therapeutics, Inc.LTM Mar 2026225.47M +9.3%+15.5%
LEGNLegend Biotech CorporationLTM Sep 2026185.87M +1.7%+5.0%
VIRVir Biotechnology, Inc.LTM Mar 2026140.99M +3.1%+1.5%
IMTXImmatics N.V.LTM Mar 2026125.95M +14.7%+22.1%
NKTXNkarta, Inc.LTM Mar 202674.08M +0.6%+19.3%
IMCRImmunocore Holdings plcLTM Mar 202650.45M +0.8%+3.3%
ATRAAtara Biotherapeutics, Inc.LTM Mar 202613.1M +49.4%+45.4%
Peer median (excluding IBRX) 163.43M+3.0%+10.3%

Competitors are the stored peer set for IBRX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue934K240K622K14.75M113.29M
Cost of Revenue0000753K
Gross Profit934K240K622K14.75M112.54M
Gross Margin100.0%100.0%100.0%100.0%99.3%
Research & Development195.96M248.15M232.37M190.14M207.88M
Selling, General & Admin135.26M102.71M129.62M168.78M147.18M
Operating Expenses331.21M351.54M362.87M358.93M368.56M
Depreciation & Amortization14.24M18.26M18.51M17.55M15.53M
EBITDA(320.75M)(351.88M)(478.66M)(264.43M)(223.56M)
EBITDA Margin-34341.8%-146617.1%-76955.5%-1793.4%-197.3%
Operating Income(330.28M)(351.3M)(362.25M)(344.18M)(256.03M)
Operating Margin-35361.9%-146374.2%-58239.5%-2334.2%-226.0%
Interest Income836K2.71M863K2.4M6.7M
Interest Expense14.85M47.15M86.72M131.66M112.53M
Other Income / Expenses(19.56M)(65.99M)(221.64M)(69.46M)(95.58M)
Income Before Tax(349.84M)(417.29M)(583.89M)(413.65M)(351.61M)
Pre-Tax Margin-37456.0%-173869.2%-93873.3%-2805.3%-310.4%
Income Tax Expense9K34K(40K)0(135K)
Net Income(346.79M)(416.57M)(583.2M)(413.56M)(351.4M)
Net Margin-37129.6%-173569.6%-93761.4%-2804.8%-310.2%
EPS (Basic)(0.89)(1.04)(1.15)(0.59)(0.38)
EPS (Diluted)(0.89)(1.04)(1.15)(0.62)(0.38)
Weighted Avg Shares389.23M399.9M508.64M697.31M919.86M
Weighted Avg Shares (Diluted)389.23M399.9M508.64M700.44M919.86M

ImmunityBio, Inc.

NASDAQ:IBRX

Intrinsic Alpha fair value

Locked

Current Price

$6.70

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.